Investor List:

Top Pharmaceuticals Seed Investors in New York City (131)

INVESTORSINTRO STRENGTHSWEET SPOT (RANGE)INVESTMENT LOCATIONSTOP INVESTMENT CATEGORIES
Photo of David Bonita, General Partner at OrbiMed
OrbiMed
n/a
$4.0M
($1M - $75.0M)
Investors in New York (NY)
+17
Photo of Jonathan Rosenbaum, Managing Director at Insight Partners
n/a
$25.0M
($10.0M - $350.0M)
Investors in New York (NY)
Investors in AI (Series B), Investors in Pharmaceuticals (Seed), Investors in Education (Series B), Investors in Education (Series A), Investors in Enterprise (Series B), Investors in Education (Seed), Investors in Pharmaceuticals (Series B), Investors in AI (Seed), Investors in FinTech (Series B), Investors in AI (Series A), Investors in Pharmaceuticals (Series A), Investors in AI (Seed), Investors in SaaS (Series B), Investors in Enterprise (Series A), Investors in Education (Seed), Investors in FinTech (Seed), Investors in New York City (Other Lists), Investors in SaaS (Seed), Investors in Pharmaceuticals (Seed), Investors in AI (Series A), Investors in Education (Series A), Investors in Enterprise (Series A), Investors in FinTech (Series A), Investors in SaaS (Series A), Investors in Pharmaceuticals (Series A), Investors in AI (Series B), Investors in FinTech (Series B), Investors in Enterprise (Series B), Investors in Education (Series B), Investors in Pharmaceuticals (Series B), Investors in SaaS (Series B), Investors in SaaS (Series A), Investors in Enterprise (Seed), Investors in FinTech (Series A), Investors in FinTech (Seed), Investors in SaaS (Seed), Investors in Enterprise (Seed)
+33
n/a
$10.0M
($250K - $20.0M)
Investors in New York City
+30
Photo of Michael Aberman, Partner at SOSV
n/a
$1M
($100K - $2.0M)
Investors in New York (NY)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A)
+5
Photo of W. Carter Neild, Managing Partner at OrbiMed
OrbiMed
n/a
$4.0M
($1M - $75.0M)
Investors in New York (NY)
Photo of Tim Shannon, General Partner at Canaan Partners
n/a
$10.0M
($250K - $20.0M)
Investors in Westport (CT), Investors in New York (NY)
Photo of Carl  Gordon, Managing Partner at OrbiMed
OrbiMed
n/a
$4.0M
($1M - $75.0M)
Investors in New York (NY)
+15
n/a
$25.0M
($2.0M - $50.0M)
Investors in New York City
+21